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Introduction: The identification of new progenitor cell sources is important for cell-based tissue engineering
strategies, understanding regional tissue regeneration, and modulating local microenvironments and immune
response. However, there are no reports that describe the identification and isolation of mesenchymal progenitor
cells (MPCs) from paranasal sinus mucosa, and compare the properties of MPCs between tissue sources within the
sinonasal cavity. We report here the identification of MPCs in the maxillary sinus (MS) and ethmoid sinus (ES).
Furthermore, we contrast these MPCs in the same individuals with MPCs from two additional head and neck tissue
sources of the inferior turbinate (IT) and tonsil (T).
Methods: These four MPC sources were exhaustively compared for morphology, colony-forming potential,
proliferation capability, immunophenotype, multilineage differentiation potential, and ability to produce
soluble factors.
Results: MS-, ES, IT-, and T-MPCs showed similar morphologies and surface phenotypes, as well as adipogenic,
osteogenic, and chondrogenic differentiation capacity by immunohistochemistry and qRT-PCR for defined lineage-
specific genes. However, we noted that the colony-forming potential and proliferation capability of ES-MPCs were
distinctly higher than other MPCs. All MPCs constitutively, or upon stimulation, secrete large amounts of IL-6, IL-8,
IL-10, IFN-γ, and TGF-β. After stimulation with TNF-α and IFN-γ, ES-MPCs notably demonstrated significantly higher
secretion of IL-6 and IL-10 than other MPCs.
Conclusions: ES-MPCs may be a uniquely promising source of MPCs due to their high proliferation ability and
superior capacity toward secretion of immunomodulatory cytokines.Introduction
Mesenchymal progenitor cells (MPCs) represent an im-
portant progenitor cell population with multipotent ca-
pabilities which may have high utility for translational
clinical applications. MPCs can be isolated from bone
marrow (BM-MPCs) and differentiate into several mes-
enchymal lineages both in vitro and in vivo, such as
bone [1-3], cartilage [1,2], adipose tissue [1,2] and mus-
cle [1,4]. In addition to their multilineage potential,
MPCs have been shown to possess immunomodulatory
properties with therapeutic potential to prevent graft-
versus-host disease (GVHD) in allogeneic hematopoietic
cell transplantation [5]. Given these properties, MPCs have* Correspondence: JNayak@ohns.stanford.edu
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reproduction in any medium, provided the oremerged as a promising tool for therapeutic applications in
tissue engineering and regenerative medicine [6,7].
Although the BM has been the main source for the
isolation of multipotent MPCs, BM procurement has
numerous potential downsides, including pain, donor
site morbidity and poor cell yield upon harvest. In the
search for more optimal donor site substitutes, MPCs
have been isolated from a number of adult tissues, in-
cluding adipose tissue [8], synovial membrane [9], mus-
cle [10,11], dermis [11], skin [12], trabecular bone [13],
thymus [14], salivary gland [15], palatine tonsil [16] and,
most recently, nasal mucosa [17].
The paranasal sinuses are a group of four paired air-
filled cavities of the upper respiratory system that sur-
round the central nasal airway. Two of these sinuses, the
maxillary sinus (MS) and ethmoid sinus (ES), are both
present at birth, and are the most common sites of sinona-
sal inflammation in both pediatric and adult populations. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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preciated source of donor tissue that is readily accessible
to any ear, nose and throat surgeon during endoscopic
sinus surgery. As many superficial undiseased mucosal
sites of the sinonasal tract still require dissection to
provide patency to the deep-seated sinuses, this fairly
abundant ‘bystander’ regional tissue can be uneventfully
harvested from patients in a minimally invasive, virtually
painless, low morbidity manner. Although recent studies
suggest the presence of MPCs in the mucosa of the infe-
rior turbinate (IT) within the nasal cavity, and osteopro-
genitor cells in the MS mucosa [17,19,20], there are no
reports identifying and isolating MPCs from the paranasal
sinus mucosa or comparing the properties of MPCs by tis-
sue source within the sinonasal cavity. The purpose of this
study was to assess the presence and properties of MPCs
in human MS and ES mucosa and to compare MPCs iso-
lated from four different sources (MS, ES, IT and tonsil) in
the same individuals with respect to their morphology,
proliferation capacity, colony forming capacity, immuno-
phenotype, ability to generate soluble regulatory cytokines
and potential for multilineage differentiation.
Materials and methods
Isolation and culture of MPCs
After obtaining Institutional Review Board (IRB) appro-
val of Pusan National University Hospital, healthy, unin-
fected mucosal tissue specimens from the MS, ES and
IT were obtained from adult patients undergoing endo-
scopic sinus surgery for chronic rhinosinusitis. Thirteen
patients (eight males, five females) were enrolled from
ages 20 to 56 years, (mean = 35.7 years) who each provi-
ded informed consent under an IRB-approved protocol.
Tonsil (T) tissues were obtained after informed consent
from four of these patients undergoing both endoscopic
sinus surgery for chronic rhinosinusitis and tonsillec-
tomy for obstructive sleep apnea. Tonsils served as a
control tissue population for this study. All specimens
were completely normal macroscopically and histology
showed no evidence of inflammation in the part of the
specimen that was obtained.
To isolate IT, MS, ES and T-derived MPCs, mucosa
and tonsil tissues were washed extensively with an equal
volume of phosphate-buffered saline (PBS) in order to
remove the majority of erythrocytes. Tissues were cut
into 1 to 2 mm pieces, and digested with 0.075% colla-
genase type I (Sigma, St. Louis, MO, USA) at 37°C for
30 minutes. Enzyme activity was neutralized with α-
modified Eagle’s medium (α-MEM) containing 10% fetal
bovine serum (FBS) and the sample was centrifuged at
1,200 × g for 10 minutes. The cell pellet was filtered
through a 100 μm nylon mesh to remove cellular deb-
ris and adhered overnight at 37°C/5% CO2 in control
medium (α-MEM, 10% FBS, 100 unit/ml of penicillin,100 μg/ml of streptomycin) on 100 mm petri dishes. Fol-
lowing this incubation step, plates were washed extensively
with PBS to remove residual non-adherent red blood cells.
The remaining cells were maintained at 37°C/5% CO2 in
control media. One-week later, when the monolayer of
adherent cells reached confluence, cells were trypsinized
(0.05% Trypsin-EDTA; Sigma), resuspended in α-MEM
containing 10% FBS, and subcultured at a concentration of
2,000 cells/cm3. Each subsequent passage via subculture
occurred on a weekly basis under similar conditions.
Colony-forming and cell proliferation assay
To evaluate colony number per inoculated cell, 100 ad-
herent cells at the second passage were re-plated and
cultured for seven days on 60 cm2 dishes in standard
culture medium. The cells were subsequently fixed with
4% paraformaldehyde, stained with 0.5% crystal violet
for five minutes, and washed twice with distilled water.
The number of colonies was then counted. Colonies less
than 2 mm in diameter and faintly stained colonies were
not further assessed.
To estimate cell proliferation, adherent cells at this
same passage above were plated onto 24-well plates (104
cells/well) in α-MEM containing 10% FBS. MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assays were performed one, two, three and four days
after plating using our established protocol [21]. Briefly,
growth medium containing 0.25 mg/ml MTT (Sigma)
was added to each well, which was further incubated
at 37°C for 20 minutes. After incubation, the MTT
solution was removed and 0.2 ml/well dimethyl sulfoxide
(DMSO; Sigma) was added to solubilize the cells. The op-
tical absorption of each well was measured at 540 nm with
a microtiter ELISA reader (ELX800, BioTek, Winooski,
VT, USA).
Immunophenotypic analysis
Flow cytometric analysis was used to characterize the
phenotypes of the MPCs. For experiments, we used the
third or fourth passage of MPCs. At least 50,000 cells (in
100 μL PBS, 0.5% bovine serum albumin (BSA), 2 mmol/L
EDTA) were incubated with fluorescein isothiocyanate-
labeled monoclonal antibodies against human CD90,
CD44, CD73, HLA-ABC, CD45, CD31 and HLA-DR (BD
Biosciences Clontech, Palo Alto, CA, USA) or with the re-
spective isotype control antibody. After washing, labeled
cells were analyzed by flow cytometry using fluorescence-
activated cell sorting (FACS) Caliber flow cytometer and
Cell Quest Pro software (BD Biosciences, San Diego,
CA USA).
Multilineage differentiation of MPCs
MPCS were analyzed for their capacity to differentiate
toward the adipogenic, osteogenic Fand chondrogenic
Table 1 Reverse transcription-polymerase chain reaction
primer sequences
Primer name Sequence (5′-3′) Size (bp)
GAPDH Sense: GGACTCATGACCACAGTCCATGCC 152
Antisense: TCAGGGATGACCTTGCCCACA
LPL Sense: GAGATTTCTCTGTATGGCACC 276
Antisense: CTGCAAATGAGACACTTTCTC
PPARγ Sense: TGAATGTGAAGCCCATTGAA 161
Antisense: CTGCAGTAGCTGCACGTGTT
ALP Sense: TGGAGCTTCAGAAGCTCAACACCA 454
Antisense: ATCTCGTTGTCTGAGTACCAGTCC
OC Sense: ATGAGAGCCCTCACACTCCTC 294
Antisense: GCCGTAGAAGCGCCGATAGGC
AGN Sense: TGCGGGTCAACAGTGCCTATC 182
Antisense: CACGATGCCTTTCACCACGAC
COL2A1 Sense: GGAAACTTTGCTGCCCAGATG 167
Antisense: TCACCAGGTTCACCAGGATTGC
AGN, aggrecan; ALP, alkaline phosphatase; bp, base pairs; COL2A1, collagen
type II α1; GAPDH, glyceraldehydes-3-phosphate dehydrogenase; LPL, lipoprotein
lipase; OC, osteocalcin; PPARγ, peroxisome proliferator-activated receptor-gamma.
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for these experiments.
Adipogenic differentiation was induced by culturing
MPCs for three weeks in adipogenic media (1 μM de-
xamethasone, 100 μg/ml 3-isobutyl-1 methylxanthine
(IBMX), 5 μg/ml insulin and 60 μM indomethacine,
and 10% FBS in α-MEM) and assessed using an Oil Red
O stain as an indicator of intracellular lipid accumulation.
Prior to staining, the cells were fixed for 15 minutes at
room temperature in 70% ethanol. The cells were incu-
bated in 2% Oil Red O reagent for one hour at room
temperature. Excess stain was removed by washing with
70% ethanol, followed by several changes of distilled
water. To quantify adipogenic differentiation, the amount
of Oil Red O was determined by measuring the optical
density at 510 nm with a spectrophotometer after treat-
ment with isopropyl alcohol. The results were then nor-
malized to the protein contents of the samples.
Osteogenic differentiation was induced by culturing
MPCs for three weeks in osteogenic media (0.1 mM de-
xamethasone, 10 uM β-glycerophosphate, 50 μg/ml as-
corbic acid and 10% FBS in α-MEM) and examined for
extracellular matrix calcification by Alizarin red S stain-
ing. For Alizarin red S staining, the cells were fixed with
70% ethanol and washed with distilled water. The cells
were incubated in 2% Alizarin red solution for 15
minutes at room temperature, and washed several times
with distilled water to clear the stain. In order to evalu-
ate alkaline phosphate (ALP) activity, an early marker of
osteoblast activity, samples were treated with 100 μl 50
mM p-nitrophenyl phosphatase hexahydrate containing
1 nm MgCl2, and incubated for 20 minutes at 37°C. To
quantify osteogenic differentiation, optical densities were
measured at 405 nm with a spectrophotometer. The re-
sults were then normalized to the protein content within
the samples.
Chondrogenic differentiation was induced using the
micromass culture technique. Briefly, 10 μl of a concen-
trated MSC suspension (3 × 105 cells/ml) were plated
into the center of each well and allowed to attach at
37°C for two hours. Chondrogenic media (CM,1% FBS,
0.1 mM dexamethasone (Sigma), 50 μg/ml ascorbic acid,
ITS + 1 (insulin-transferrin-selenium; Sigma), 10 ng/ml
TGF-β1 (Sigma), 10 ng/ml in α-MEM) was gently over-
laid so as not to detach the cell nodules, and cultures
were maintained in CM for four weeks prior to analysis.
Chondrogenesis was confirmed by immunohistochemis-
try. Micromasses were harvested after four weeks culture
and immediately frozen in optimum cutting temperature
medium. Sections 10 μm thick were cut and fixed in 4%
paraformaldehyde. For collagen type II staining, sections
were first blocked with 10% horse serum, incubated with
purified anti-mouse collagen type II antibody (BD Bio-
science, San Jose, CA, USA) for one hour, and washedwith PBS (pH 7.4). Cells with bound antibodies were de-
tected with a peroxidase substrate kit (Vectastain ABC
kit; Vector Laboratories, Burlingame, CA, USA). Sec-
tions were washed, counterstained with hematoxylin and
examined by light microscopy.
Quantitative real-time reverse transcription-polymerase
chain reaction
For quantitative real-time polymerase chain reaction
(qRT-PCR) analysis, total RNA was isolated from each
of the cell donor cultures from Day 21 monolayer cultured
cells using Trizol reagent (Invitrogen Corp., Carlsbad, CA,
USA). Isolated RNA was then reverse-transcribed using
random hexamers. RT-PCR was performed using 10 ng
of cDNA and SYBR Green mix (Bio-Rad Laboratories,
Hercules, CA, USA). Transcript-specific primers were de-
signed based on GenBank cDNA sequences listed in
Table 1: (a) signature markers of adipogenesis: lipo-
protein lipase (LPL) and peroxisome proliferator-activated
receptor-gamma (PPARγ), (b) markers of osteogenesis:
ALP and osteocalcin (OC), (c) markers of chondrogenesis:
collagen type II α1 (COL2A1) and aggrecan (AGN). Ex-
pression levels are presented as the fold increase over that
of glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
using the formula 2(ΔCt), where ΔCt = Ct of target gene -
Ct of GAPDH.
Detection of cytokine secretion by MPCs
Secretion of interleukin (IL)-2, IL-4, IL-5, IL-6, IL-8,
IL-10, IL-13, tumor necrosis factor (TNF)-α, inter-
feron (INF)-γ, transforming growth factor (TGF)-β was
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Wiesbaden, Germany), according to the manufacturer’s
protocol. Third-passage cells were washed three times
with Dulbecco’s modified Eagle’s medium (DMEM) and
cultured for 48 hours in standard medium at a concentra-
tion of 1 × 106 cells/ml. To evaluate the responsiveness of
MPCs to immunological signals, cells were incubated with
TNF-α (1,000 U/ml) and IFN-γ (400 U/ml) for 16 hours.
Supernatant samples were run in triplicate and compared
to standard curves.
Statistical analysis
All experiments were repeated at least in triplicate. Data
are presented as mean ± SEM from all tissue specimens
isolated. Statistical significance was assessed by one-way
repeated analysis of variance (ANOVA), followed by
Tukey’s honest significant difference (HSD) post hoc
test using SPSS software package version 13.0 (SPSS
Inc., Chicago, IL, USA). A value of P <0.05 was consi-
dered significant.
Results
Isolation and proliferation characteristics of MS-MPCs,
ES-MPCs, IT-MPCs and T-MPCs
At an initial plating density of 1 × 106 cells/cm2, MS, ES,
IT and T-derived fibroblastoid cells formed a monolayer
four to five days after initial plating. These putative MS,
ES, IT and T-derived MPCs (IT, MS, ES and T-MPCs)
were of serpiginous or fibroblast-like morphology similar
to previously reported adipose tissue and bone marrow-
derived MPCs (Figure 1A). This morphology was main-
tained during passage in monolayer culture.
To examine the frequency of MPCs present from each
cell source, we observed the colony-forming capabilities
of each MSC type and counted the number of colonies
in dishes stained with crystal violet (Figure 1B). The
number of colonies per 100 inoculated cells, that is,
colony-forming efficiency, was significantly higher in
ES than MS, IT and T tissues (P = 0.004). However,
no significant differences were found among the MS,
IT and T groups (Figure 1C).
The proliferation capability of MS-MPCs, ES-MPCs,
IT-MPCs and T-MPCs was analyzed by MTT assay. Al-
though plated at the same initial cell number (1 × 104
cells/well), ES-MPCs proliferated at a faster rate com-
pared with MS-MPCs, IT-MPCs and T-MPCs at days 3
and 4 (P = 0.001 and P <0.001, respectively) (Figure 1D).
On days 1 and 2, no significant differences were noted
between any of the groups.
Immunophenotypic characterization
To further characterize these cells, cell surface markers
were examined by flow cytometry. MPCs from all sour-
ces were positive for CD90, CD44, CD73, and HLA-ABCand negative for CD45, CD31, and HLA-DR, with no sig-
nificant differences noted between the four cell source
populations (Figure 2).
Adipogenic differentiation capacity
Adipogenic differentiation was demonstrated by the ac-
cumulation of neutral lipid vacuoles indicated by the Oil
Red O staining. After adipogenic induction, a significant
fraction of the cells contained multiple, intracellular
lipid-filled droplets that stained by Oil Red O in MS-,
ES-, IT- and T-MPCs (Figure 3A). No red staining was
detected in control groups (data not shown). Optical
densities were significantly higher in MS-, ES-, IT- and
T-MPCs groups than in the control group (P = 0.003,
P = 0.002, P = 0.003 and P = 0.017, respectively). How-
ever, there were no significant differences among any of
the MPCs groups (Figure 3B).
The expression of LPL and PPARγ were analyzed by
qRT-PCR after 21 days of induction. The expression of
LPL and PPARγ were both up-regulated during adipo-
genesis in all MPCs groups. However, there were no sig-
nificant differences in the expression level of two
markers among any of the MPCs groups (Figure 3C,D).
Osteogenic differentiation capacity
Osteogenic differentiation was confirmed by the detec-
tion of an osteogenic phenotype consisting of an increased
expression of ALP and the deposition of Alizarin red S
stained mineralized matrix, calcification appearing as red
regions within the cell monolayer. Consistent with osteo-
genesis, several red regions in Alizarin red S staining were
observed in MS-, ES-, IT- and T-MPCs (Figure 4A). No
red regions were detected in control groups (data not
shown). ALP activities were significantly higher in MS-,
ES-, IT- and T-MPCs groups than in the control group
(P <0.001, P <0.001, P <0.001 and P = 0.006, respectively).
However, there were no significant differences among any
of the MPCs groups (Figure 4B).
The expression of osteogenic genes was assessed by
qRT-PCR. Up-regulated mRNA expression of ALP and
OC was observed in all MPCs groups. No significant dif-
ferences in the expression level of these genes were seen
among any of the MPCs groups (Figure 4C,D).
Chondrogenic differentiation capacity
Compared with the control group, chondrogenic dif-
ferentiation of MPCs was confirmed by the formation
of a sphere in micromass culture. The size of a sphere was
not different among the MPCs groups (Figure 5A). Chon-
drogenesis was further studied by analyzing the expression
of cartilage-specific type II collagen. There was no signifi-
cant difference in the expression of collagen type II among
any of the MPCs groups.
Figure 1 Isolation characteristics and proliferation capability. (A) The fibroblast-like morphology of MPCs is shown after initial plating and at
passage 2 (original magnification 100×, scale bar = 30 μm). (B) A total of 100 adherent cells were cultured in 60 cm2 dishes for seven days and
stained with 0.5% crystal violet. (C) The colony number per adherent cells was significantly higher in ES than IT, MS and T. (D) ES-MPCs proliferated
at a faster rate compared with MS-, IT and T-MPCs at days 3 and 4 by MTT assay. Data are expressed as the mean ± SEM. * P = 0.004, †P = 0.001,
‡ P <0.001. ES, ethmoid sinus; IT, inferior turbinate; MPCs, mesenchymal progenitor cells; MS, maxillary sinus; T, tonsil.
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ES-, IT- and T-MPCs groups. However, there were no
significant differences in the expression level of these
genes between the MPCs groups (Figure 5B,C).
Analysis of cytokine secretion in MPCs
To test whether MPCs display immune cell-like features,
secretion of cytokines and response to inflammatory sig-
nals were analyzed. MS-, ES-, IT- and T-MPCs constitu-
tively secreted IL-6, IL-8, IFN-γ and TGF- β that easily
exceeded 1 pg/ml under standard culture conditions, al-
though IL-2, IL-4, IL-5, IL-10, IL-13 and TNF-α were
secreted less than 1 pg/ml or not detected (Figure 6).Furthermore, we investigated the responsiveness of MPCs
to immunological signals and exposed these cells to a
panel of cytokines, including TNF-α and IFN-γ. MS-,
ES-, IT- and T-MPCs upon exogenous stimulation se-
creted much larger amounts of IL-6, IL-8, IL-10 and
TGF-β. Interestingly, the expression of IL-6 and IL-10
were significantly higher in the ES-MPCs than MS-
MPCs, IT-MPCs and T-MPCs (P = 0.001 and P <0.001,
respectively).
Discussion
MPCs were initially isolated from bone marrow but are
now shown to reside in almost all adult organs and
Figure 2 Immunophenotypic analysis of MS-, ES, IT- and T-MPCs. Flow cytometry showed positive expression for CD90, CD44, CD73
and HLA-ABC and negative expression for CD45, CD31 and HLA-DR. The values represent the mean percentage of all assessed cells
positively stained by the respective antibodies. ES, ethmoid sinus; IT, inferior turbinate; MPCs, mesenchymal progenitor cells; MS, maxillary sinus;
T, tonsil.
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only on species-specific factors but also on the tissue
sources from which the MPCs were harvested. Further-
more, the isolation of MPCs from new tissue sources is
critical as currently defined donor tissues have specific
disadvantages, including large donor site morbidity as
well as a dearth of MPCs upon harvest, requiring gener-
ous amounts of donor tissue to be harvested.
Ideal progenitor cell populations would be autologous
cells that can be harvested without difficulty from each
patient, manipulated efficiently in vitro, and autoim-
planted back into the same patient [23]. In this study,
we focused on the sinus mucosa, which is an easily ac-
cessible donor tissue site that is routinely acquired as part
of endoscopic sinus surgery, an exceedingly commonly
performed surgical procedure throughout the world. Add-
itionally, harvest of these tissues is ethically acceptable,
since healthy ‘bystander’ mucosal specimens that are ac-
quired during surgery are routinely discarded. In thisreport, we isolated and cultured MPCs from the mucosa
of maxillary and ethmoid sinuses, and mesenchymal-like
characteristics were able to be identified in both MS-
MPCs and ES-MPCs, such as surface marker expression,
plastic adherence, self-renewal and multilineage differenti-
ation capacity. In addition, we compared these two MPCs
to IT-MPCs and T-MPCs in the same individuals. The lat-
ter cells were recently reported as an alternative source of
MPCs in order to choose more optimal cell source for
particular therapeutic purposes.
The respiratory mucosa of maxillary and ethmoid si-
nus is composed of a superficial epithelial lining and
the underlying submucosa/lamina propria. The outer
surface is a ciliated pseudostratified epithelium, while
the deeper portion underneath a basement membrane
is a highly vascularized connective tissue. Although it
is difficult to determine the precise location of MPCs
within the sinus mucosa, a number of studies have
suggested that MPCs are likely to be localized within
Figure 3 Comparative analysis of adipogenic differentiation capacity of MS-, ES, IT- and T-MPCs. (A) Adipogenesis was detected by the
formation of multiple, intracellular lipid-filled droplets stained with Oil Red O after induction for 21 days (original magnification 100×, scale bar =
50 μm). (B) In the spectrophotometric analysis of Oil Red O staining, optical densities were significantly higher in MS-, ES-, IT- and T-MPCs groups
than the control group. No significant differences were found between any of the MPCs groups. The expression of specific adipogenic genes was
evaluated by real-time qRT-PCR. LPL (C) and PPARγ (D) were up-regulated during adipogenesis in all MPCs groups. However, there were no
significant differences in the expression level of two markers among any of the MPCs groups. Data are expressed as the mean ± SEM. *, ‡ P = 0.003, †,
‡‡ P = 0.002, § P = 0.017, ǁ P = 0.005, ¶, ** P <0.001, †† P = 0.010, §§, ǁǁ P = 0.002, ¶¶ P = 0.020. ES, ethmoid sinus; IT, inferior turbinate; LPL, lipoprotein
lipase; MPCs, mesenchymal progenitor cells; MS, maxillary sinus; PPARγ, peroxisome proliferator-activated receptor-gamma; T, tonsil.
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Figure 4 Comparative analysis of osteogenic differentiation capacity of MS-, ES, IT- and T-MPCs. (A) Osteogenesis was demonstrated by
several dark red regions stained with Alizarin Red S, indicative of calcified extracellular matrix under osteogenic differentiation condition (original
magnification 100×, scale bar = 50 μm). (B) In the analysis of alkaline phosphatase activity, optical densities were significantly higher in MS-, ES,
IT- and T-MPCs groups than control group. However, there were no significant differences among any of the MPCs groups. Up-regulation of the
expression of specific osteogenic genes, ALP (C) and OC (D), were evaluated by real-time qRT-PCR. Data are expressed as the mean ± SEM. *, †, ‡,
ǁ, ¶, **, ‡‡, §§, ǁǁ P <0.001, § P = 0.006, †† P = 0.042, ¶¶ P = 0.040. ALP, alkaline phosphate; ES, ethmoid sinus; IT, inferior turbinate; MPCs,
mesenchymal progenitor cells; MS, maxillary sinus; OC, osteocalcin; T, tonsil.
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Figure 5 Comparative analysis of chondrogenic differentiation capacity of MS-, ES, IT- and T-MPCs. (A) Chondrogenesis was
demonstrated by the formation of a sphere and type II collagen expression. There were no differences in the size of sphere and the
immunohistochemical staining for type II collagen among any of the MPCs groups (original magnification 100×, scale bar = 50 μm). The
expression of specific chondrogenic genes, COL2A1 (B) and AGN (C), was evaluated by real-time qRT-PCR. COL2A1 and AGN were up-regulated
during chondrogenesis in all MPCs groups. However, there were no significant differences in the expression level of two markers among any of
the MPCs groups. Data are expressed as the mean ± SEM. *, †, ‡, ǁ, ¶, ** P <0.001, § P = 0.002, †† P = 0.005. AGN, aggrecan; COL2A1, collagen
type II α1; ES, ethmoid sinus; IT, inferior turbinate; MPCs, mesenchymal progenitor cells; MS, maxillary sinus; T, tonsil.
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[24-26].
The morphological features of MS-MPCs, ES-MPCs,
IT-MPCs and T-MPCs were similar to those descri-
bed for BM-MPCs and showed plastic adherence and
fibroblast-like growth. After an initial lag phase for four to
five days, these adherent cells proliferated actively and be-
came nearly confluent. Although adherent cells give rise
to a mixed population of cells, only progenitor cells would
possess the properties of self-renewal and multilineage
potential. To identify colony-forming MPCs and to de-
termine their proliferation capacity, the colony-formingefficiency and MTT assays were evaluated. Among the
four MPCs derived from MS, ES, IT and tonsil, we un-
expectedly discovered that ES-MPCs have the highest
colony-forming potential and proliferation capability in
culture. Furthermore, we demonstrate that ES-MPCs may
potentially have higher proliferation capacity than BM-
MPCs as previous studies have revealed that T-MPCs pos-
sess faster population doubling time than BM-MPCs [16].
Several previous reports have documented the expres-
sion of phenotypic markers in MPCs [27-29]. Immuno-
phenotypic analysis of this study showed that the surface
marker profiles of MS-, ES-, IT- and T-MPCs were
Figure 6 (See legend on next page.)
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Figure 6 Cytokine secretion in MS-, ES, IT- and T-MPCs. IL-6, IL-8, IFN-γ and TGF-β were constitutively secreted and easily exceeded
1 pg/ml under standard culture conditions. However, IL-2, IL-4, IL-5, IL-10, IL-13 and TNF-α were secreted less than 1 pg/ml or not detected.
MS-, ES-, IT- and T-MPCs upon stimulation secreted a large amount of IL-6, IL-8, IL-10 and TGF-β. The expression of IL-6 and IL-10 were significantly
higher in the ES-MPCs than MS-, IT- and T-MPCs. Data are expressed as the mean ± SEM. *, ǁ, ¶, **, ‡‡‡, §§§, ǁǁǁ P = 0.001, † P = 0.009, ‡, §§, ¶¶,
¶¶¶ P <0.001, § P = 0.006, †† P = 0.003, ‡‡ P = 0.004, ǁǁ P = 0.006, *** P = 0.042, ††† P = 0.046. ES, ethmoid sinus; IT, inferior turbinate; MPCs,
mesenchymal progenitor cells; MS, maxillary sinus; T, tonsil.
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These cells were positive for CD90, CD44 and CD73 but
negative for CD45, CD31 and HLA-DR.
Multilineage differentiation potential has been con-
sidered an important quality of MPCs. As shown by
histochemical or immunohistochemical staining, optical
density and qRT-PCR for defined lineage-specific marker
genes, MS-, ES-, IT- and T-MPCs shared the capacity to
differentiate into adipogenic, osteogenic and chondro-
genic lineages in the presence of tissue-specific induction
medium. However, there were no significant differences
in multilineage differentiation capacity among any of the
MPC groups.
MPCs have recently been demonstrated to suppress
T-, B-, natural killer (NK) and dendritic cell activities,
thus exerting an immunoregulatory influence both in
vitro and in vivo [5,30-33]. Although the immunosup-
pressive mechanisms of MPCs remain to be clarified, it
is generally accepted that the ability of MPCs to modu-
late immune responses relies on cell contact-dependent
mechanisms and select soluble factors secreted by MPCs.
Several soluble factors have been proposed to mediate the
immunosuppressive effect, including IL-6, IL-8, IL-10,
IFN-γ, TGF-β, granulocyte-colony stimulating factor
(G-CSF) and granulocyte macrophage-colony stimulat-
ing factor (GM-CSF) [23,34]. In the present study, all
of MSC populations studied constitutively, or upon stimu-
lation, secrete large amounts of IL-6, IL-8, IL-10, IFN-γ
and TGF-β. Interestingly, after stimulation with TNF-α
and IFN-γ, we detected significantly higher secretions of
IL-6 and IL-10 by ES-MPCs. IL-6 has been known to
stimulate antibody secretion in human B cells [35] and
IL-10 has been recognized to inhibit the differentiation
of dendritic cells and increase the number of regula-
tory T cells [23]. Taken together, these data show that ES-
MPCs may be a highly robust source for MSC-mediated
immunomodulation.
Our studies also revealed similarities and differences
among four different sources of MPCs from the same in-
dividual. MS-, ES-, IT and T-MPCs can be regarded as
potential cell sources for possible tissue engineering, re-
generative medicine and immunomodulatory strategies.
It is thought that clinical applications of MPCs may
be based not only on their differentiation potential,
but more likely on the abundance, frequency, prolife-
ration potential and immunosuppressive capacity. Inthis regard, ES-MPCs may be an ideal source of MPCs
in respect to easily repeatable accessibility without
donor site morbidity, highest proliferation ability and el-
evated secretion of soluble factors. These differences in
properties of MPCs isolated from the ES and MS might
be explained by differences in embryological develop-
ment, as the endochondral origin of the ES makes these
regions ontologically different from the other paranasal
sinuses [36].
Human ethmoid sinus mucosa can be easily obtained
via transnasal endoscopic approach without incision
under topical anesthesia at outpatient clinics. Respiratory
epithelium appears to regenerate mostly from undiffer-
entiated basal cells from adjacent non-injured areas. If
we preserve the mucoperiosteum over the bone, and
thereby avoid areas of bone exposure, mucosal dysfunc-
tion can be reduced after removal of sinus mucosa. Espe-
cially, the ethmoid bulla is typically a rather large anterior
ethmoid air cell and the most consistent and recognizable
of the ethmoid cells. Most of the ethmoid sinus mucosa
can be easily obtained from the inferior and medial por-
tion of the ethmoid bulla. Therefore, major complications,
such as a cerebrospinal fluid leak or orbital hemorrhage,
rarely develop.
This study is not devoid of inherent limitations. This
in vitro study does not necessarily translate into MPCs
that can or will exhibit the same potential in vivo. An-
other consideration for the future clinical use of MPCs
and notably ES-MPCs, is that these cells may be isolated
from sinus mucosa that are frequently inflamed and in-
fused with inflammatory mediators, and, therefore, indi-
vidual differences in the patient mucosa due to local
tissue effects may affect the properties of the MPCs. Fu-
ture studies will address the exact characteristics and
localization of sinus-derived MPCs and elucidate the ef-
fects of inflammatory disease on MPCs both in vitro and
in vivo.
Conclusions
This study demonstrates that MPCs with multilineage
differentiation potential and immunosuppressive property
can be obtained from MS and ES mucosa. Most notably,
ES-MPCs could be a novel and promising abundant
source of MPCs due to their high proliferation ability
and superior capacity toward secretion of immunomodu-
latory cytokines.
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